|
1
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer Worldwide incidence and trends.
Gastroenterology. 127((Suppl 1)): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cabrera R and Nelson DR: Review article:
The management of hepatocellular carcinoma. Aliment Pharmacol Ther.
31:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Caldwell S and Park SH: The epidemiology
of hepatocellular cancer: From the perspectives of public health
problem to tumor biology. J Gastroenterol. 44(Suppl 19): 96–101.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosch FX, Ribes J and Borràs J:
Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsuchiya N, Sawada Y, Endo I, et al:
Biomarkers for the early diagnosis of hepatocellular carcinoma.
World J Gastroenterol. 21:10573–10583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics biogenesis,
mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity, microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: T arget recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vasudevan S, Tong Y and Steitz JA:
Switching from repression to activation, microRNAs can up-regulate
translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo Q, Li X, Gao Y, Long Y, Chen L, Huang
Y and Fang L: MiRNA-497 regulates cell growth and invasion by
targeting cyclin E1 in breast cancer. Cancer Cell Int. 13:952013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Poell JB, van Haastert RJ, de Gunst T,
Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Noort PI,
Prevost GP, Schaapveld RQ, et al: A functional screen identifies
specific microRNAs capable of inhibiting human melanoma cell
viability. PLoS One. 7:e435692012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012.PubMed/NCBI
|
|
17
|
Lehmann U, Streichert T, Otto B, Albat C,
Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH and Länger
F: Identification of differentially expressed microRNAs in human
male breast cancer. BMC Cancer. 10:1092010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Özata DM, Caramuta S, Velázquez-Fernández
D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C and
Lui WO: The role of microRNA deregulation in the pathogenesis of
adrenocortical carcinoma. Endocr Relat Cancer. 18:643–655. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Furuta M, Kozaki K, Tanimoto K, Tanaka S,
Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The
tumor-suppressive miR-497-195 cluster targets multiple cell-cycle
regulators in hepatocellular carcinoma. PLoS One. 8:e601552013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
LeRoith D and Helman L: The new kid on the
block(ade) of the IGF-1 receptor. Cancer Cell. 5:201–202. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morrione A, DeAngelis T and Baserga R:
Failure of the bovine papillomavirus to transform mouse embryo
fibroblasts with a targeted disruption of the insulin-like growth
factor I receptor genes. J Virol. 69:5300–5303. 1995.PubMed/NCBI
|
|
25
|
Valentinis B and Baserga R: IGF-I receptor
signalling in transformation and differentiation. Mol Pathol.
54:133–137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hellawell GO, Turner GD, Davies DR,
Poulsom R, Brewster SF and Macaulay VM: Expression of the type 1
insulin-like growth factor receptor is up-regulated in primary
prostate cancer and commonly persists in metastatic disease. Cancer
Res. 62:2942–2950. 2002.PubMed/NCBI
|
|
27
|
Tomizawa M, Shinozaki F, Sugiyama T,
Yamamoto S, Sueishi M and Yoshida T: Insulin-like growth factor-I
receptor in proliferation and motility of pancreatic cancer. World
J Gastroenterol. 16:1854–1858. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kornprat P, Rehak P, Rüschoff J and
Langner C: Expression of IGF-I, IGF-II, and IGF-IR in gallbladder
carcinoma. Histopathology. J Clin Pathol. 59:202–206. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weber MM, Fottner C, Liu SB, Jung MC,
Engelhardt D and Baretton GB: Overexpression of the insulin-like
growth factor I receptor in human colon carcinomas. Cancer.
95:2086–2095. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sekharam M, Zhao H, Sun M, Fang Q, Zhang
Q, Yuan Z, Dan HC, Boulware D, Cheng JQ and Coppola D: Insulin-like
growth factor 1 receptor enhances invasion and induces resistance
to apoptosis of colon cancer cells through the Akt/Bcl-x(L)
pathway. Cancer Res. 63:7708–7716. 2003.PubMed/NCBI
|
|
31
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Markman B, Atzori F, Pérez-García J,
Tabernero J and Baselga J: Status of PI3K inhibition and biomarker
development in cancer therapeutics. Ann Oncol. 21:683–691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Scharf JG, Schmidt-Sandte W, Pahernik SA,
Ramadori G, Braulke T and Hartmann H: Characterization of the
insulin-like growth factor axis in a human hepatoma cell line
(PLC). Carcinogenesis. 19:2121–2128. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang YC, Wang XP, Zhang LY, Song AL, Kou
ZM and Li XS: Effect of blocking IGF-I receptor on growth of human
hepatocellular carcinoma cells. World J Gastroenterol.
12:3977–3982. 2006.PubMed/NCBI
|
|
36
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma, The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
National Research Council (US) Committee
for the Update of the Guide for the Care Use of Laboratory Animals
Guide for the Care and Use of Laboratory Animals (8th). Washington,
WA: National Academies Press. 2011.
|
|
39
|
Ni QF, Tian Y, Kong LL, Lu YT, Ding WZ and
Kong LB: Latexin exhibits tumor suppressor potential in
hepatocellular carcinoma. Oncol Rep. 31:1364–1372. 2014.PubMed/NCBI
|
|
40
|
Anwar SL and Lehmann U: MicroRNAs:
Emerging novel clinical biomarkers for hepatocellular carcinomas. J
Clin Med. 4:1631–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Llovet JM and Bruix J: Molecular targeted
therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vigneri P, Frasca F, Sciacca L, Pandini G
and Vigneri R: Diabetes and cancer. Endocr Relat Cancer.
16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Laca L, Dedinska I, Miklusica J, Janik J,
Palkoci B and Pindura M: Surgical treatment of hepatocellular
carcinoma. Bratisl Lek Listy. 116:539–541. 2015.PubMed/NCBI
|
|
44
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics monitoring and therapeutics.
Histopathology. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Khandwala HM, McCutcheon IE, Flyvbjerg A
and Friend KE: The effects of insulin-like growth factors on
tumorigenesis and neoplastic growth. Endocr Rev. 21:215–244. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu X, Sakon M, Nagano H, Hiraoka N,
Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, et
al: Akt2 expression correlates with prognosis of human
hepatocellular carcinoma. Oncol Rep. 11:25–32. 2004.PubMed/NCBI
|
|
48
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sjögren K, Liu JL, Blad K, Skrtic S, Vidal
O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, et
al: Liver-derived insulin-like growth factor I (IGF-I) is the
principal source of IGF-I in blood but is not required for
postnatal body growth in mice. Proc Natl Acad Sci USA.
96:7088–7092. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wu J and Zhu AX: Targeting insulin-like
growth factor axis in hepatocellular carcinoma. J Hematol Oncol.
4:302011. View Article : Google Scholar : PubMed/NCBI
|
